Search
Hengrui Medicine Receives Approval for Adebelimab Injection Clinical Trials
2025-08-13 /
Read about 0 minute
Author：小编
A subsidiary of Hengrui Medicine has recently obtained the 'Approval Notice for Drug Clinical Trials' from the National Medical Products Administration for both SHR-A2102 and Adebelimab Injection, marking the imminent commencement of clinical trials. SHR-A2102, an antibody-drug conjugate specifically targeting Nectin-4, and Adebelimab, a humanized anti-PD-L1 monoclonal antibody, are both independently developed by Hengrui Medicine. Prior to market launch, both drugs must successfully navigate the clinical trial phase, followed by rigorous review and approval processes.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
